SHEET 1 OF 3

ATTORNEY'S DKT NO. APPLICATION NO. INFORMATION DISCLOSURE 032367-451 09/456,429 APPLICANT **CITATION** ູ່ Yu Hua Ji, et al. DEC 5 8 5000 ILING DATE GROUP **b**ecember 8, 1999 1614 PTO-1449 U.S. PATENT BOGUMENTS **EXAMINER'S FILING INITIALS** PATENT NO. DATE NAME CLASS SUBCLASS DATE 3,845,770 11/5/74 Theeuwes, et al. 4/27/82 4,326,525 Swanson, et al. 4,771,057 9/13/88 Knaus, et al. 2/20/90 4,902,514 Barclay, et al. 2/12/91 4,992,445 Lawter, et al. 3/19/91 5,001,139 Lawter, et al. 5,011,472 4/30/91 Aebischer, et al. 6/11/91 5,023,252 Hseih 10/31/95 Agrafiotis, et al. 5,463,564 5,571,827 11/5/96 Barberich, et al. 5.616.345 4/1/97 Geoghegan, et al. 5,686,495 11/11/97 Goldwin, et al. 5,846,839 12/8/98 Gallop, et al. 5.891.643 4/6/99 Fesik, et al. **FOREIGN PATENT DOCUMENTS EXAMINER'S** PATENT NO. DATE COUNTRY CLASS **SUBCLASS INITIALS** Yes No 2,240,325 6/11/98 Canada WO 92/05802 4/16/92 WO 93/06121 4/1/93 æ PCT WO 97/21445 1/19/97 WO 98/00439 1/8/98 PG7 WO 98/34948 8/13/98 Pe1 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Alker, D., et al. "Formation, Synthetic Utility and Strucutre Elucidation of a 2-Bromomethyl 1,4-Dihydropyridine." Tetrahedron Letts. 31: 1479-1482 (1990) Arrowsmith, et al. "Long-Acting Dihydropyridine Calcium Antagonists. 1. 2-Alkoxymethyl Derivatives Incorporating Basic Substituents." J. Med Chem. 29: 1696-1702 (1986).

m \$16/01

INFORMATION DISCLASURE CITATION DEC 5 8 5000

ATTORNEY'S DKT NO. APPLICATION NO. 032367-451 09/456,429 **A**PPLICANT Yu-Hua Ji, et al. JAN 0 4 200

FILING DATE December 8, 1999

	PTO-1449 PTO-1449 PTO-1449 PTO-1449				
	THE CONTRACTOR OF THE CONTRACT				
au	Balboni, B., et al. "Calcium Antagonists: Vinylogues and bivalent ligands related to nifedipine." <i>Pharmazie</i> . 43: 318 (1988).				
m	Bezprozvanny, I., et al. "Voltage-Dependent Blockade of Diverse Types of Voltage-Gated Ca ²⁺ Channels Expressed in <i>Xenopus</i> Oocytes by the Ca ²⁺ Channel Antagonist Mibefradil (Ro 40-5967)." Molec. Pharmacol. 48: 540-549 (1995).				
M	Bossert, et al. "4-Aruldihydropyridines, a New Class of Highly Active Calcium Antagonists." <i>Angew. Chem. Int. Ed.</i> 20: 762-769 (1997).				
M	Brittain, et al. "Relaxation of K ⁺ Contracted Rabbit Aortic Strips Implies Calcium Channel Blockade." <i>Physiologist</i> , 28: 325 (1985).				
M	Brenner, et al. "Encoded combinatorial chemistry." <i>Proc. Natl. Acad. Sci., USA</i> , 89: 5181 (1992).				
\sim	Cremers, et al. "Effects of the Novel T-Type Calcium Channel Antagonist Mibefradil on Human Myocardial Contractility in Comparison with Nifedipine and Verapamil." <i>J. Cardiovasc. Pharmacol.</i> 29: 692-696 (1997).				
	Cross, PE., et al. "Selective Class III Antiarrhythmic Agents. 1. Bis(arylalkyl)amines." <i>J. Med. Chem.</i> 33(4): 1151 (1989).				
M	Denyer, et al. "HTS Approaches to Voltage-Gated Ion Channel Drug Discovery." Drug Discovery today. 3(7): 323-332 (1998)				
0	Eltze, et al. "Stereoselective Inhibition of Thromboxane-Induced Coronary Vasoconstriction by 1,4-Dihydropyridine Calcium Channel Antagonists." <i>Chirality</i> , 2: 233-240 (1990).				
N	Gordeev, et al. "A General and Efficient Solid Phase Synthesis of Qynazoline-2,4-diones." Tetrahedron Lett. 38(10): 1729-1732 (1997)				
m	Gordeev, et al. "Approaches to Combinatorial synthesis of Heterocycles: A Solid Phase Synthesis of 1,4-Dihydropyridines." J. Org. Chem. 61: 924-928 (1996)				
\sim	Hess, et al. "Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists." <i>Nature</i> 311: 538-544 (1984).				
M	Hockerman, et al. "Molecular Determinants of Drug Binding and Action on L-Type Calcium Channels." <i>Annu. Rev. Pharmacol. Toxicol.</i> 37: 361-96 (1997).				
m	Joslyn, et al. "Dimeric 1,4-Dihydropyridines as Calcium Channel Antagonists." <i>J. Med. Chem.</i> 31: 1489-1492 (1988).				
M	Kenny, et al. "The Application of High-throughput Screening to Novel Lead Discovery." Progress in Drug Research. Edited by Ernst Jucker. Herhauser Verlag: Basel, 1998, Vol. 1, 246-269.				
sk	Kokubun, et al., "Studies on Ca Channels in Intact Cardiac Cells: Voltage-Dependent Effects and Cooperative Interactions of Dihydropyridine Enantiomers" <i>Molec. Pharmacol.</i> 30: 571-584 (1986).				
ah	Liang, R., et al. "Parallel synthesis and screening of a solid phase carbohydrate library." <i>Science</i> , 274: 1520 (1996).				
M	Osterrieder, W., et al. "In Vitro Phamacologic Profile of Ro 40-5967, a Novel Ca ²⁺ Channel Blocker with Potent Vasodilator but Weak Inotropic Action." <i>Cardiovasc. Pharmacol.</i> 13: 754-9 (1989).				
\mathcal{N}	PD-029361. Current drug report.				
1	Portoghese, P.S. "The Role of Concepts in Structure-Activity Relationship Studies of Opioid Ligands." J. Med. Chem. 35(11): 1927-1937 (1992).				
MA	Rampe, D., et al., "New synthetic ligands for L-type voltage-gated calcium channels." <i>Prog. Drug. Res.</i> 40: 191-238 (1993).				

	SHEET 3	OF 3
APPLICATI	ION NO.	

INFOR	MATION DISCLOSTIFE	032367-451 APPLICANT	09/456,429			
CITATION Ju-Hua Ji, et al.						
	PTO-1449	Dicember 8, 1999	GROUP 1614			
RE	Rovnyak, G.C., et al. "Dihydropyrimidine Calcium Channel Blockers. 4. Basic 3-Substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic Acid Ester. Potent Antihypertensive Agents." <i>J. Med. Chem.</i> 35: 3254-3263 (1992).					
m	Shuker, S.B., et al. "Discovering High-Affinity Ligands for Proteins, SAR by NMR." Science. 274: 1531-1534 (1996)					
ny	Tokuma, Y., et al. "Stereoselective pharmacokinetics of dihydropyridine calcium antagonists." J. Chromatography A., 694: 181-193 (1995).					
An	Yuen, P., et al. "Synthesis and SAR of sibustituted 1,2,3,4-tetrahydroisoquinoloines as N type Calcium channel blockers." <i>Bioorg and Med. Chem. Lett.</i> 8: 2415 (1998).					
M	Zeng, et al. "Automated Analytical/Preparative High Performance Liquid Chromatography-Mass Spectrometry System for the Rapid Characterization and Purification of Compound Libraries." <i>J. Chrom. A.</i> 794:3-13 (1998).					
EXAMINER		DATE CONSIDERED	6/01			

ATTORNEY'S DKT NO.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.